Contact us
Mobile menu not yet fully implemented
COST – European Cooperation in Science and Technology – is the European intergovernmental framework for the coordination of national or regional funded research.
manhei.to@fwo.be
+32 2 550 15 55
COST – European Cooperation in Science and Technology – is the European intergovernmental framework for the coordination of national or regional funded research.
COST plays an important role in the development of the European research area. COST's mission is to strengthen Europe in scientific and technological research through the support of European cooperation and interaction between European researchers.
COST offers financing for the coordination of pan-European research networks (COST actions). The actual research is financed via other (national or regional) channels.
The main features of COST are:
COST is financed with specific budget lines from the EU Framework Programmes. At present, COST supports some 300 ongoing actions and reaches out to more than 30,000 researchers across Europe.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
